Comparative Pharmacology
Head-to-head clinical analysis: THEOPHYL 225 versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOPHYL 225 versus XOPENEX HFA.
THEOPHYL-225 vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator